Connect with Us
602 Park Point Drive, Suite 225, Golden, CO 80401 – +1 303.495.2073
© 2024 Medical Affairs Professional Society (MAPS). All Rights Reserved Worldwide.
This paper synthesizes the views of senior global Medical Affairs leaders to provide a unified vision for the future of Medical Affairs. As such, this document represents the first consensus position by executives in Medical Affairs of our evolving roles, activities, and value in society, industry, teams and as individuals (detailing each in turn). By 2030, Medical Affairs will solidify its transition from executional to strategic, and the function will come to represent the voice of the patient within industry. We will not only disseminate evidence but also lead evidence generation activities that inform the real-world use of marketed and emerging treatments. Also in this time frame, we will solidify the role of Medical Affairs as industry’s external earpiece, gleaning insights from our interactions with the health care ecosystem that drive understanding of patient, payer, and provider needs and opinions. Throughout this evolution, the true north of Medical Affairs remains the same: to ensure that our science and technologies benefit patients.
At the MAPS 2022 Global Annual Meeting, we sat down with Riad Dirani, Vice President of Global Health Economics and Outcomes Research at Teva Pharmaceuticals, and Omar Dabbous, Vice President of Global Health Economics and Outcomes Research and Real World Evidence at AveXis to chat about the structure and activities of HEOR within Medical Affairs.
MAPS speaks with Tim Mikhelashvili and Riaz Abbas about innovative approaches to compliant patient education including collaborations with patient associations, peer navigators and the emerging use of social media.
MAPS members represent the full range of Medical Affairs professionals, from those leading or working in large organizations, to those tasked with starting a Medical Affairs function at startup or emerging organizations. Here, MAPS speaks with Lobna Salem, Regional Chief Medical officer Developed Markets& Japan Australia and New Zealand at Viatris, about the process of building Medical Affairs from scratch.
Medical Affairs is a function within the biopharmaceutical, consumer healthcare, and MedTech industries that sits alongside other functions including Research & Development (R&D) and Commercial as one of the strategic pillars of the industry. R&D develops new drugs, devices and diagnostics; Commercial markets and sells these products; and Medical Affairs generates and communicates data that help healthcare professionals (HCPs), payors, policy makers and others make informed decisions that ensure the best use of treatments to benefit patients. In this way, Medical Affairs plays a vital role in providing scientific evidence and understanding to appropriately change clinical practice.
Just as there are many roles within R&D and Commercial, individuals working within Medical Affairs are responsible for many activities, especially including the following:
At the MAPS 2022 Global Annual Meeting, MAPS sits down to chat with José Borbolla, Global Executive Medical Director at Esai, and Augusto Grinspan, VP Medical Affairs and Head LATAM with Merck KGaA about developments in the practice and direction of Medical Affairs in Latin America. Augusto and José are also co-chairs of the MAPS Latin America Chapter.
This webinar will analyze the current state of Medical Affairs in Japan, highlight progress made and provide suggestions on what we can do together to make Medical Affairs in Japan even more effective.
This webinar will be covering:
1.   MA in Japan today: progress and highlights
a.   Leadership requirements in Japan to bring MA to the next level
b.   MA has become more strategic across all companies
c.    What are the competencies required to succeed?
2.   Looking into the future of MA in Japan
a.   How to engage more with Patients/Patient Advocacy groups
b.   How to bring more value to customers, scientific leaders and health systems
c.    How to better engage academia and health authority group through scientific exchange
3.   Opportunities for improving effectiveness
a.   Differentiation of MSL and Medical Rep roles- how are companies differentiating despite the regulations?
MAPS speaks with Tim Mikhelashvili, PharmD, CEO & Co-Founder, Amedea Pharma, Inc. and Riaz Abbas, Learning and Performance Lead, JAPAC Medical, Amgen about innovative approaches to Medical Affairs External Education.
One topic of discussion at the MAPS 2022 Global Annual Meeting was the role of Medical Affairs in patient engagement. Specifically, with patients taking more ownership decisions surrounding care, should Medical Affairs be engaging with patients and/or patient communities in a compliant way? To go even further, should Medical Affairs be the entity within the organization that "owns" patient engagement? Here, Marija Geertsen, VP of Medical Affairs at Lundbeck shares her opinion -- and the story of how her opinion changed during the course of the meeting.
As Medical Affairs professionals, it's easy to focus on the tasks that are right in front of us everyday. In this interview with Monica de Abadal, SVP and Head of Medical Affairs, North America we sat down at the MAPS 2022 Global Annual Meeting to take a step back. Here is how Medical Affairs benefits patients and society. Watch the full interview here.
602 Park Point Drive, Suite 225, Golden, CO 80401 – +1 303.495.2073
© 2024 Medical Affairs Professional Society (MAPS). All Rights Reserved Worldwide.